These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23436565)

  • 21. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience.
    Peerschke EI; Castellone DD; Ledford-Kraemer M; Van Cott EM; Meijer P;
    Am J Clin Pathol; 2009 Apr; 131(4):552-8. PubMed ID: 19289591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pearls and pitfalls in factor inhibitor assays.
    Adcock DM; Favaloro EJ
    Int J Lab Hematol; 2015 May; 37 Suppl 1():52-60. PubMed ID: 25976961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A variation of the Nijmegen-Bethesda assay using heat or a novel heat/cold pretreatment for the detection of FIX inhibitors in the presence of residual FIX activity.
    Millner AH; Tiefenbacher S; Robinson M; Boesen HT
    Int J Lab Hematol; 2016 Dec; 38(6):639-647. PubMed ID: 27545696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Factor VIII/IX inhibitor testing practices in the United Kingdom: Results of a UKHCDO and UKNEQAS national survey.
    Batty P; Riddell A; Kitchen S; Sardo Infirri S; Walker I; Woods T; Jennings I; Hart DP
    Haemophilia; 2021 May; 27(3):490-499. PubMed ID: 33650732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating laboratory approaches to the identification of lupus anticoagulants: a diagnostic challenge from the RCPA Haematology QAP.
    Bonar R; Favaloro E; Zebeljan D; Rosenfeld D; Kershaw G; Mohammed S; Marsden K; Hertzberg M
    Pathology; 2012 Apr; 44(3):240-7. PubMed ID: 22183703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Laboratory testing for factor inhibitors.
    Favaloro EJ; Verbruggen B; Miller CH
    Haemophilia; 2014 May; 20 Suppl 4():94-8. PubMed ID: 24762283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. False-positive results in ELISA-based anti FVIII antibody assay may occur with lupus anticoagulant and phospholipid antibodies.
    Sahud M; Zhukov O; Mo K; Popov J; Dlott J
    Haemophilia; 2012 Sep; 18(5):777-81. PubMed ID: 22458845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The factor VIII inhibitor assays can be standardized: results of a workshop.
    Verbruggen B; Dardikh M; Polenewen R; van Duren C; Meijer P
    J Thromb Haemost; 2011 Oct; 9(10):2003-8. PubMed ID: 21854536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A.
    Valke LLFG; Verhagen MJA; Mulders BTPM; Polenewen R; Blijlevens NMA; Jansen JH; Mansouritorghabeh H; Elsheikh E; Reipert BM; Turecek PL; O'Donnell JS; Rijpma SR; Schols SEM; van Heerde WL; Meijer D
    Thromb Res; 2023 Nov; 231():112-120. PubMed ID: 37844518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Association of Hemophilia Centre Directors of Canada. Factor VIII/IX Subcommittee of Scientific and Standardization Committee of International Society on Thrombosis and Haemostasis.
    Giles AR; Verbruggen B; Rivard GE; Teitel J; Walker I
    Thromb Haemost; 1998 Apr; 79(4):872-5. PubMed ID: 9569207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A standardized method for measuring anti-F VIII: C inhibitors in haemophilia A by coagulation inhibition in agarose gel.
    Jorquera JI; Carmona E; Aznar JA; Peiró A; Sánchez-Cuenca JM
    Thromb Haemost; 1985 Aug; 54(2):377-80. PubMed ID: 3936211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Harmonisation of factor VIII:C assay results: study within the framework of the Dutch project 'Calibration 2000'.
    van den Besselaar AM; Haas FJ; Kuypers AW
    Br J Haematol; 2006 Jan; 132(1):75-9. PubMed ID: 16371022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.
    Kraiem I; Hadhri S; El Omri H; Sassi R; Chaabani W; Ennabli S; Skouri H
    Ann Biol Clin (Paris); 2012; 70(6):659-65. PubMed ID: 23207810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a novel automated screening method for detection of FVIII Inhibitors.
    Evans MS; Donaldson KJ; Eyster ME
    Int J Lab Hematol; 2017 Apr; 39(2):185-190. PubMed ID: 28133956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnosis and quantification of factor VIII inhibitors.
    Verbruggen B
    Haemophilia; 2010 May; 16(102):20-4. PubMed ID: 19228204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
    Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
    Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Frequency of factor VIII inhibitor in the patients with hemophilia A and environmental risk factors for inhibitor development].
    Yan ZY; Fan LK; Li KX; Wang XY; Hua BL; Wang SJ; Zhao YQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):580-3. PubMed ID: 19968075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
    Mazurier C; Parquet-Gernez A; Goudemand M
    Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.